The firm believes that as Lymphir launches, it will become a value driver for its parent, Citius. Oncology drug Lymphir has achieved significant milestones in its development and approval process ...
Citius Pharma ( (CTXR)) has released its Q4 ... and the accuracy of their predictions so investors know who to trust when making investment decisions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback